Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR1 | Q08345 | 11/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628778 | 0.94 | TSHR (0.36) | DDR1CA12CA9TSHR | |
| SCHEMBL4627730 | 0.89 | DDR1 (0.37) | DDR1CA12CA9AR | |
| SCHEMBL4627637 | 0.87 | DDR1 (0.37) | DDR1AR | |
| SCHEMBL4627649 | 0.84 | CA12 (0.38) | DDR1CA12CA9AR | |
| SCHEMBL4628111 | 0.83 | DDR1 (0.36) | DDR1AR | |
| SCHEMBL1661288 | 0.82 | DDR1 (0.37) | DDR1CA12CA9AR | |
| SCHEMBL2391466 | 0.82 | DDR1 (0.38) | DDR1CA12CA9AR | |
| SCHEMBL2390017 | 0.82 | DDR1 (0.38) | DDR1CA12CA9AR | |
| SCHEMBL4628707 | 0.82 | DDR1 (0.37) | DDR1CA12CA9AR | |
| SCHEMBL1663166 | 0.79 | AR (0.36) | DDR1CA12CA9AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655666-B2 | Substituted 1H-quinazoline-2,4-diones useful as AMPA receptor ligands | NOVARTIS AG (CH) | 2010-02-02 | — | — | US | disclosed |
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153836-A1 | N-(2,4-Dioxo-1,4-dihydro-2H-quinazolin-3-yl)-methanesulfonamide derivatives; condensation, cyclization, reduction; AMPA (A-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonists; schizophrenia, bipolar disorders, Parkinson's Disease, antiepileptic agents; psychological disorders | GRIN2A, GRIN1, GRIN2D | DDR1 3161/4885CA12 3261/4885CA9 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.